Ajanta Pharma
Ajanta Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.
From Ajanta Pharma's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Ajanta Pharma expects continued healthy growth momentum across business segments.
- India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years.
- U.S. generics showed 52% growth in Q3 FY26; 8 product launches in last 12 months; double-digit growth expected in FY27 but likely at a slower pace than FY26.
- Asia branded business projected to deliver mid-single-digit to high-single-digit growth, with some softness expected in certain markets.
- Africa branded business expected to post low-double-digit growth.
- GLP-1 products set to launch in emerging markets from FY27, with first revenue expected around FY28.
- Plans to expand into new geographies (e.g., Latin America) and therapeutic segments to support growth towards $1 billion revenue.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Ajanta Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure during the 9-month period stood at Rs. 235 crores and is expected to be in line with the full-year guidance of around Rs. 300 crores. (Page 5)
- Continued strategic investment in products, brand, and people across the branded generic portfolio is ongoing, as reflected by a 24% increase in other expenses compared to last year. (Page 5)
- There is an increased thrust on acquisitions, which might influence future payout decisions and strategic direction. The Board will decide on this after Q4 results. (Page 9)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ajanta Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Ajanta Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.4K Cr, net profit ₹267 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ajanta Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Ajanta Pharma Q3 FY26 results?
Ajanta Pharma expects continued healthy growth momentum across business segments. - India branded business grew 19% in Q3 FY26; gynaecology segment seen as a future growth driver over 2-3 years. - U.S. Full year FY'26 growth guidance: mid-teens revenue growth expected (Page 6). - EBITDA margin expected to maintain at around 27% ±1% for FY'26 (Page 5). - Profit After Tax (PAT) growth: 18% YoY in Q3 FY'26, 14% for 9 months FY'26; PAT margin stable at 20% (Page 5). - U.S.
What is Ajanta Pharma share price analysis?
Ajanta Pharma currently shows a neutral. The stock trades at a P/E of 40.1 with a market cap of ₹45,483 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ajanta Pharma planning capital expenditure?
Capital expenditure during the 9-month period stood at Rs.
Keep Ajanta Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.